Vertex Pharmaceuticals

Vertex reported second-quarter revenue of $3.3 billion, a 12% increase year over year. Trikafta continued to anchor the cystic fibrosis franchise, comprising 75% of sales, while next-generation Alyftrek rose to 17% of sales. Vertex raised its 2026 revenue outlook by 96 basis points at the midpoint.

Why it matters: While the CF franchise continues to generate strong cash flows that help de‑risk pipeline funding, the focus is shifting to whether Vertex's non-CF assets, such as pain drug Journavx and phase 3 candidate povetacicept for IgAN, can scale into durable revenue drivers. Journavx's revenue and prescriptions filled grew 71% and 53%, respectively, but reimbursement infrastructure continues to lag demand, with gross-to-net normalization delayed to the first half of 2027. We view this as a launch-related headwind, with easing payer restrictions supporting multi-billion-dollar annual revenue during our forecast period. Competitor Otsuka's IgAN drug, Voyxact, just published two-year data showing improvements in kidney function, while povetacicept's accelerated approval rests on a 36-week proteinuria surrogate. Povetacicept is administered via an autoinjector as opposed to Voyxact's prefilled syringe, but if Vertex's comparable long-term data disappoints, its edge could shrink.

The bottom line: We maintain our fair value estimate of $450 per share for narrow-moat Vertex. Shares are trading about 5% above our valuation. While higher operating expenses offset the modest revenue outlook increase, the quarter reinforced our view that Vertex is effectively reinvesting CF-cash flows to build multiple long-term growth platforms. We maintain our 11% annualized revenue growth forecast over the next five years.

Coming up: We await the US regulatory action date in November for povetacicept in IgAN, the first potential approval in Vertex's renal franchise. We assign this candidate a 90% probability of approval.

We maintain Vertex's fair value estimate of $450 per share.

Vertex acquired Crinetics Pharmaceuticals for $10 billion, adding promising endocrinology assets, including approved acromegaly therapy Palsonify and atumelnant, a phase 3 once-daily oral candidate for congenital adrenal hyperplasia. Palsonify competes with approved injectable therapies from Pfizer, Novartis, and Ipsen, but its convenient once-daily oral formulation could help drive patient uptake. Atumelnant would face Neurocrine's twice-daily Crenessity. We assign atumelnant a 65% probability of approval. Management targets more than $5 billion in combined peak annual sales for Palsonify and atumelnant. We estimate probability-weighted atumelnant sales of nearly $3 billion by 2035, making it the deal's primary source of risk and upside.

After reassessing Vertex's risk profile, we recently lowered our WACC to 8% from 9%. Our 0.6 beta reflects low exposure to economic cycles, minimal leverage, and predictable CF revenue.

Vertex’s 2024 acquisition of Alpine Immune Sciences for $4.9 billion in cash expanded its kidney-disease portfolio through povetacicept, which is being evaluated for IgA nephropathy, a chronic kidney condition that can lead to end-stage renal disease. Positive phase 3 data for povetacicept showed a 49.8% reduction in proteinuria compared with placebo and met primary and all secondary endpoints. We assign this candidate a 90% probability of approval and expect a launch in early 2027. We forecast blockbuster potential, with sales exceeding $1 billion annually by 2030.

Alyftrek strengthens Vertex's CF franchise with highly effective once-daily dosing and reinforces its leadership in the CF market. We expect it to become the new CF standard of care, with patients shifting from Trikafta/Kaftrio's twice-daily regimen over our 10-year forecast. Alyftrek covers 31 additional rare CF mutations, and it extends patent protection through 2039, compared with 2037 for Trikafta.

We forecast more than $13 billion in revenue in 2026, reflecting nearly 10% growth. We expect operating expenses to remain elevated at roughly 47% of sales over the next four years as Vertex supports recent product launches and invests in its pipeline. Even so, we project operating margins will steadily expand to approximately 46% by the end of our 10-year forecast period. We have a positive outlook for Vertex and project 11% annualized revenue growth over the next five years.

Vertex continues to advance the global launch of its gene therapy, Casgevy, for sickle cell disease and transfusion-dependent beta thalassemia. We believe Casgevy can command strong pricing and ultimately become a blockbuster product.

Journavx, Vertex's nonopioid pain signal inhibitor for acute pain, is another commercial priority. We expect Journavx to contribute about 9% of total revenue by the end of our forecast period, supported by a large addressable market. Management aims to triple Journavx prescriptions in 2026 from 550,000 in 2025, supported by a broader prescriber base, expanded coverage, and patient discounts. However, we see near-term headwinds given its $15.50 per pill price versus low-single-digit opioids. Longer-term growth will depend on broader payer coverage, expanded use across pain settings, and fewer discounts. We project $250 million in 2026 Journavx sales.

In May 2026, Vertex ended its nearly decade-long mRNA collaboration with Moderna on VX-522 after tolerability challenges in this inhaled therapy for CF patients lacking a functional CFTR protein. We had already incorporated this risk in our model, assigning only a 10% probability of approval. While Vertex remains committed to serving all CF patients, this outcome reinforces our view that treating patients without CFTR protein is inherently harder. Future growth is more dependent on extending the existing CF franchise, successfully commercializing non-CF assets, and advancing pipeline candidates.

Vertex's portfolio of patent-protected cystic fibrosis drugs forms the basis of our narrow economic moat rating. The key moat source is intangible assets, as lengthy patents extending to 2039 and two decades of accumulated scientific expertise give Vertex first-mover status that rivals have been unable to replicate. Vertex's cystic fibrosis drugs are the only disease-modifying drugs on the market that restore cystic fibrosis transmembrane conductance regulator, or CFTR.

Cystic fibrosis is a genetic disorder affecting roughly 112,000 people worldwide that causes a progressive and deadly decline in the function of the lungs and digestive system. While the number of patients is small, Vertex has strong pricing power, and its six-figure pricing for its disease-modifying drugs generated nearly $11.8 billion in cystic fibrosis revenue in 2025.

Vertex’s two main revenue-generating drugs are Trikafta and Alyftrek, which generated 93% of the firm’s $12 billion of revenue in 2025. Vertex’s core patents covering Trikafta expire in 2037 and Alyftrek in 2039. Vertex firmly fits within the narrow moat definition, supported by durable competitive advantages and expected returns on invested capital that exceed its weighted average cost of capital for at least the next decade.

Vertex has benefited from a welcoming regulatory and commercial environment because CF is rare and lacks disease-modifying treatments. Vertex has built on its intellectual property by developing more efficacious drug combinations with easier administration, which increasingly capture more patients with various CF mutations. The eligible population has grown from only 1,000 US patients when Vertex’s first CF drug, Kalydeco, was approved in 2012, to 95% of people with the disease in core markets today. Alyftrek (US approval in 2024 and EU approval in 2025) is a once-daily triple combination that builds on molecules in Vertex's previous CF drugs while layering in a new CFTR corrector. Switching patients to Alyftrek extends the franchise's protection to 2039. The complexity, efficacy, and unique mechanism of its medicines give Vertex a competitive advantage.

Vertex commands strong pricing power because CF is a rare, chronic condition and there are no alternative disease-modifying treatment options currently on the market. Many patients start treatment for CF in early childhood and continue throughout their lifetime. Trikafta’s US list price at launch was $311,000, and Alyftrek carries a US list price of $370,000 per year.

Vertex does not face significant competition in the cystic fibrosis market. Galapagos and AbbVie both reported lackluster results for their candidates, underscoring the high efficacy bar in Vertex's portfolio. In fact, AbbVie discontinued its CF research in 2022 after its trials failed to meet efficacy targets.

Vertex's assets and pipeline candidates outside of CF help diversify its portfolio. Vertex's $4.9 billion acquisition of Alpine Immune Sciences in April 2024 brought in povetacicept, which reported positive phase 3 data in IgA nephropathy (a chronic kidney disease) in March 2026. Management has framed povetacicept as a potential “pipeline-in-a-product,” with the possibility of addressing multiple B cell-mediated autoimmune diseases beyond IgA nephropathy. We assign a 90% probability of approval and anticipate it could generate more than $1 billion annually by 2030.

In September 2026, Vertex closed its roughly $10 billion acquisition of Crinetics Pharmaceuticals, its largest deal to date. Crinetics brings Palsonify, the first once-daily oral therapy for acromegaly, and atumelnant, a phase 3 candidate in congenital adrenal hyperplasia, which management believes could together exceed $5 billion in peak annual sales.

Elsewhere in the portfolio, Casgevy, developed with Crispr Therapeutics under a 60/40 profit share, was the world's first approved CRISPR-based therapy for sickle cell disease and transfusion dependent beta thalassemia. Patient uptake has accelerated as authorized treatment centers expand and payer coverage broadens. However, Casgevy’s complex administration and small addressable patient population for severe cases of sickle cell disease and transfusion-dependent beta thalassemia limit its scale.

In January 2025, the US approved Journavx as a first-in-class, non-opioid NaV1.8 pain signal inhibitor for the treatment of adults with moderate-to-severe acute pain. This marked the first new class of pain medication in over 20 years. Nearly 40 million US patients are prescribed opioids annually for acute pain, and roughly 900,000 Journavx prescriptions were filled in the first half of 2026 as payer coverage reached about 260 million lives. Journavx offers an alternative without the addiction risks that have made opioids a public health crisis, with the potential to become a multi-billion-dollar product during our 10-year forecast. At $15.50 per pill versus cheap generic opioids, Vertex must keep expanding coverage and utilization to build a multibillion-dollar product.

We expect returns on invested capital to remain above our 8% cost of capital. The biggest risks are the franchise's heavy revenue concentration and a rival CFTR modulator or genetic medicine matching Alyftrek's efficacy, but no such threat is near approval today. A competitor clearing that bar or clear evidence of value-destructive acquisitions would prompt us to revisit our rating.

Thanks to Vertex’s substantial CF cash flow, we think it is well positioned to advance its pipeline over the next decade and support commercialization efforts for approved drugs. Additionally, the pipeline's focus on rare indications and genetic diseases with few or no approved treatment options will likely support pricing power once approved. Therefore, we believe Vertex will be able to earn excess returns over the next 10 years, which warrants a narrow moat rating.

The firm's CF therapies are poised to dominate the lucrative market for the foreseeable future, based on the disease-modifying potential of the drugs, chronic use by patients, and limited competition.

Vertex's leading drug candidates were mostly discovered in-house, lending credibility to its drug-discovery technology and potential to generate additional pipeline candidates.

Vertex's combination therapies have lengthy patents, protecting the profitable cystic fibrosis portfolio from generics.

Vertex is highly dependent on the success of its cystic fibrosis franchise, and it could fail to diversify if its other pipeline candidates are not successful.

Pricing pressure could erode returns, given the high price tag of Vertex's therapies.

Gene-editing programs could disrupt Vertex's hold in the CF market.